Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05609968 · ClinicalTrials.gov registry record · Phase 3
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
A Phase 3 study of Carcinoma, Non-Small Cell Lung, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 3
- Development phase
- 614
- Enrollment target
- 20
- Study locations
NCT05609968 is a Phase 3 study of Carcinoma, Non-Small Cell Lung that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 614 participants, above the 319-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (92% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT05609968, a Phase 3 study of Carcinoma, Non-Small Cell Lung, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 614 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) among adults with metastatic non-small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%).
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Sacituzumab Govitecan
Study Locations (20)
Florida
- Clermont Oncology Center ( Site 0421) - Clermont
- University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0417) - Miami
- Mid Florida Hematology and Oncology Center ( Site 0416) - Orange City
Michigan
- Henry Ford Hospital ( Site 0412) - Detroit
- Profound Research LLC ( Site 0440) - Farmington Hills
New York
- Basil Clinical ( Site 0441) - Inwood
- White Plains Hospital-Center for Cancer Care ( Site 0403) - White Plains
Oregon
- Kaiser Permanente Northwest-Central Interstate--Oncology ( Site 0408) - Portland
- Oregon Health & Science University ( Site 0427) - Portland
Texas
- Houston Methodist Hospital ( Site 0419) - Houston
- Central Texas Veterans health care ( Site 0414) - Temple
Alabama
- Infirmary Cancer Care ( Site 0418) - Mobile
California
- Profound Research LLC ( Site 0444) - Oceanside
Georgia
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0407) - Marietta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 614 participants |
| Start Date | 2023-02-06 |
| Est. Completion | 2028-08-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05609968
The ClinicalTrials.gov registry entry for NCT05609968 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 614 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 319-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (92% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05609968 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT05609968 about?
NCT05609968 is a clinical study titled "Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)". The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinde...
What is the current status of trial NCT05609968?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 614 participants. The study started on 2023-02-06. Estimated completion is 2028-08-23.
What conditions does trial NCT05609968 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT05609968?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Sacituzumab Govitecan (BIOLOGICAL).
Who is sponsoring clinical trial NCT05609968?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05609968 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
-
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
RECRUITING · Phase 3
-
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.